Patents by Inventor Christopher M. Semko
Christopher M. Semko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140073788Abstract: Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.Type: ApplicationFiled: November 11, 2013Publication date: March 13, 2014Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Andrei W. Konradi, Jenifer L. Smith, Michael S. Dappen, Christopher M. Semko
-
Patent number: 8569426Abstract: Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.Type: GrantFiled: September 18, 2012Date of Patent: October 29, 2013Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Jenifer L. Smith, Michael S. Dappen, Christopher M. Semko
-
Publication number: 20130018187Abstract: Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.Type: ApplicationFiled: September 18, 2012Publication date: January 17, 2013Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Andrei W. Konradi, Jenifer L. Smith, Michael S. Dappen, Christopher M. Semko
-
Publication number: 20120329807Abstract: Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Andrei Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith
-
Patent number: 8283358Abstract: The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.Type: GrantFiled: September 4, 2009Date of Patent: October 9, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Xiaocong Michael Ye, Simeon Bowers, Albert W. Garofalo, Danielle L. Aubele, Darren Dressen, Raymond Ng, Gary Probst, Christopher M. Semko, Minghua Sun, Anh P. Truong, Michael S. Dappen
-
Patent number: 8268935Abstract: Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.Type: GrantFiled: July 7, 2006Date of Patent: September 18, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Jenifer L. Smith, Michael S. Dappen, Christopher M. Semko
-
Patent number: 8263063Abstract: Disclosed are conjugates exhibiting VLA-4 antagonistic properties. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. The conjugates of this invention are characterized as containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol. Conjugates of the invention are defined by formula I, wherein A, B, and q are described in the specification. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 8, 2010Date of Patent: September 11, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith
-
Patent number: 8030328Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: May 22, 2006Date of Patent: October 4, 2011Assignee: Elan Pharmaceuticals, Inc.Inventors: Frank Stappenbeck, Andrei Konradi, Jacek Jagodzinski, Christopher M. Semko, Ying-zi Xu, Jenifer L. Smith, Kassandra Rossiter
-
Publication number: 20110178119Abstract: The invention provides N-bicyclic sulfonamido compounds of Formula (I) wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, such as Alzheimer's disease.Type: ApplicationFiled: August 18, 2006Publication date: July 21, 2011Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Andrei W. Konradi, Matthew N. Mattson, Christopher M. Semko, Xiaocong Michael Ye
-
Publication number: 20110002876Abstract: Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: ApplicationFiled: September 8, 2010Publication date: January 6, 2011Inventors: Andrei W. Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith
-
Publication number: 20110003802Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.Type: ApplicationFiled: July 6, 2010Publication date: January 6, 2011Applicant: Elan Pharmaceuticals, Inc.Inventors: Simeon Bowers, Albert W. Garofalo, Roy K. Hom, Andrei W. Konradi, Matthew N. Mattson, Martin L. Neitzel, Christopher M. Semko, Anh P. Truong, Jing Wu, Ying-zi Xu
-
Publication number: 20100267747Abstract: The invention provides N-cyclic sulfonamido compounds of Formula I wherein A, B, R1, R1a, R2, R2a, R3 and R3a are as described in the specification. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.Type: ApplicationFiled: June 8, 2010Publication date: October 21, 2010Applicant: Elan Pharmaceuticals, Inc.Inventors: Xiaocong Michael Ye, Albert W. Garofalo, Jacek J. Jagodzinski, Andrei W. Konradi, Christopher M. Semko, Jenifer L. Smith, Ying-zi Xu
-
Patent number: 7794700Abstract: Disclosed are conjugates exhibiting VLA-4 antagonistic properties. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. The conjugates of this invention are characterized as containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol. Conjugates of the invention are defined by formula I, wherein A, B, and q are described in the specification. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: July 8, 2005Date of Patent: September 14, 2010Assignee: Elan Pharmaceuticals Inc.Inventors: Andrei Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith
-
Patent number: 7754712Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.Type: GrantFiled: December 5, 2007Date of Patent: July 13, 2010Assignee: Elan Pharmaceuticals, Inc.Inventors: Simeon Bowers, Albert W. Garofalo, Roy K. Hom, Andrei W. Konradi, Matthew N. Mattson, Martin L. Neitzel, Christopher M. Semko, Anh P. Truong, Jing Wu, Ying-zi Xu
-
Patent number: 7745454Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 7, 2004Date of Patent: June 29, 2010Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Farouz, Christopher M. Semko, Ying-Zi Xu
-
Patent number: 7732609Abstract: The invention provides N-cyclic sulfonamido compounds of Formula I wherein A, B, R1, R1a, R2, R2a, R3 and R3a are as described in the specification. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: December 1, 2006Date of Patent: June 8, 2010Assignee: Elan Pharmaceuticals, Inc.Inventors: Xiaocong Michael Ye, Albert W. Garofalo, Jacek J. Jagodinski, Andrei W. Konradi, Christopher M. Semko, Jenifer L. Smith, Ying-zi Xu
-
Publication number: 20100081680Abstract: The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.Type: ApplicationFiled: September 4, 2009Publication date: April 1, 2010Inventors: Andrei W. Konradi, Xiaocong Michael Ye, Simeon Bowers, Albert W. Garofalo, Danielle L. Aubele, Darren Dressen, Raymond Ng, Gary Probst, Christopher M. Semko, Minghua Sun, Anh P. Truong, Michael S. Dappen
-
Patent number: 7595318Abstract: Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: January 24, 2005Date of Patent: September 29, 2009Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei Konradi, Michael A. Pleiss, Jenifer L. Smith, Christopher M. Semko, Chris Vandevert
-
Patent number: 7576101Abstract: The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.Type: GrantFiled: January 26, 2004Date of Patent: August 18, 2009Assignee: Elan Pharmaceuticals, Inc.Inventors: Stephen J. Karlik, Michael A. Pleiss, Andrei W. Konradi, Francine S. Farouz, Christopher M. Semko, Darren B. Dressen, Elizabeth Messersmith, Stephen Freedman, Ted Yednock
-
Patent number: 7427628Abstract: Disclosed are compounds which bind ?4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by ?4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 26, 2006Date of Patent: September 23, 2008Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Christopher M. Semko, Ying-zi Xu, Frank Stappenbeck, Brian P. Stupi, Jenifer Smith, Michael A. Pleiss, Eugene D. Thorsett